Daniel P. Petrylak, MD, on Understanding ARV-110, an Oral PROTAC Degrader for Prostate Cancer Treatment

Posted: Tuesday, July 7, 2020

Daniel P. Petrylak, MD, of the Yale Cancer Center, discusses the proteolysis–targeting chimera degrader ARV-110, which shows antitumor activity in metastatic castration-resistant prostate cancer after other treatments, and describes next steps in the development of this agent.